This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
CRESEMBA® is as efficacious as voriconazole1
Since the early 2000s, voriconazole established itself as the primary treatment for invasive aspergillosis, helping to dramatically improve survival rates.2,3
Now CRESEMBA® builds on this important milestone, combining the efficacy of voriconazole with improved safety and tolerability.1
The pivotal SECURE trial demonstrated that CRESEMBA® achieves survival rates comparable with voriconazole in invasive aspergillosis. Both response rates and all-cause mortality were also comparable in the two treatment groups.1
Adapted from reference 1.
Double-blind, randomised-controlled, non-inferiority, multicentre international trial
Key exclusion criteria: hepatic dysfunction or moderate-to-severe renal dysfunctionb
Primary efficacy endpoint: all-cause mortality at Day 42 (ITT population)
Key secondary endpoint: overall response at the end of treatment (mITT population)
b. Hepatic dysfunction: bilirubin ≥3 x ULN, alanine transaminase or aspartate transaminase ≥5 x ULN, cirrhosis or chronic hepatic failure; moderate-to-severe renal dysfunction: calculated creatinine clearance <50 mL/min.
ITT, intention-to-treat; IV, intravenously; mITT, modified intention-to-treat; PO, per os (orally); ULN, upper limit of normal; q8h, every 8 hours; q12h, every 12 hours; q24h, every 24 hours.
Evidence suggests that CRESEMBA® has similar efficacy to liposomal amphotericin B in invasive aspergillosis4
While there are no head-to-head data to compare CRESEMBA® and liposomal amphotericin B in invasive aspergillosis, a network meta-analysis of four clinical trials showed the efficacy of CRESEMBA® was similar to liposomal amphotericin B:4
Adapted from reference 4.
AmB, amphotericin B; CI, confidence interval; ITT, intention-to-treat; OR, odds ratio.
Prescribing Information:
CRESEMBA® (isavuconazole)
PP-CRB-IND-0472 July 2022
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.